In the current issue of the Netherlands Journal of Medicine, inflammatory bowel disease (IBD) specialists from the Dutch University Medical Centres publish their guidelines for the use of infliximab in patients with Crohn’s disease. 1 Infliximab is a monoclonal antibody to tumour necrosis factor-alpha (TNF-a) and is the first biological therapy registered and approved for the treatment of this chronic inflammatory gastrointestinal disorder. In these guidelines, the authors give a detailed and very practical overview of all aspects related to the use of infliximab. The indications and the effectiveness of the drug in each of these indications are given, based on the results from the controlled studies, together with practical guidelines on dosing, interval and monitoring of patients. The second part of the guidelines deals with safety aspects of infliximab. The authors need to be congratulated for this large and detailed piece of work. This manuscript provides very useful and practical flowcharts that will undoubtedly help the (Dutch) gastroenterologist in treating patients with Crohn’s disease.